Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Guggenheim analyst Brad Canino reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $40 price target.
Barclays analyst Etzer Darout maintains Summit Therapeutics (NASDAQ:SMMT) with a Underweight and raises the price target fro...
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the pri...
Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from ...
Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late...
JMP Securities analyst Reni J. Benjamin reiterates Summit Therapeutics (NASDAQ:SMMT) with a Market Outperform and maintains ...
Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck.
Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This...
